Related Experiment Video

Updated: Jun 24, 2025

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

3.6K

System analysis based on Anoikis-related genes identifies MAPK1 as a novel therapy target for osteosarcoma with

Zhouwei Wu1,2, Jiapei Yu1,2, Tao Han3,2

  • 1Department of Orthopedics, the Second Affiliated Hospital, Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, 325000, China.

BMC Musculoskeletal Disorders
|June 4, 2024
PubMed
Abstract

Insights

We developed a new risk score model using Anoikis-related genes to predict osteosarcoma prognosis. This model aids clinicians and identifies MAPK1 as a potential therapeutic target for osteosarcoma treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genomics

Background:

  • Osteosarcoma (OS) is a prevalent pediatric bone cancer with a poor prognosis.
  • Anoikis, a mode of cell death, has unexplored roles in OS.

Purpose of the Study:

  • To investigate the role of Anoikis-related genes in osteosarcoma.
  • To develop a prognostic model for OS based on Anoikis-related genes.
  • To explore the relationship between these genes, the tumor microenvironment, and drug sensitivity.

Main Methods:

  • Differential gene expression analysis between metastatic and non-metastatic OS groups.
  • Machine learning algorithms (LASSO, SVM-RFE) for gene selection.
  • Cox regression for prognostic gene identification and risk score development.
  • Correlation analysis with tumor microenvironment and drug sensitivity data.

Main Results:

  • A novel prognostic model was developed using three Anoikis-related genes: MAPK1, MYC, and EDIL3.
  • The model demonstrated reliability in survival and ROC analyses.
  • Prognostic genes correlated with immune cell infiltration; aberrant expression of MAPK1 and MYC was observed in OS cells.
  • Nilotinib showed potential to induce OS cell apoptosis and downregulate MAPK1.

Conclusions:

  • A novel Anoikis-related risk score model can aid clinical prognosis assessment for osteosarcoma patients.
  • Tumor immune microenvironment and drug sensitivity analyses offer insights into OS mechanisms.
  • MAPK1 presents a potential therapeutic target for neoadjuvant chemotherapy in osteosarcoma.
Keywords:
AnoikisDrug resistanceMAPK1OsteosarcomaPrognostic model

More Related Videos

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models04:25

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

9.1K
Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

7.2K

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K